BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

136 related articles for article (PubMed ID: 8053886)

  • 21. Modified Bagshawe's regimen in high-risk gestational trophoblastic disease.
    Wong LC; Choo YC; Ma HK
    Gynecol Oncol; 1986 Jan; 23(1):87-93. PubMed ID: 3002917
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Successful salvage therapy of resistant gestational trophoblastic disease with etoposide, methotrexate, dactinomycin, vincristine, and cyclophosphamide.
    Gallion HH; van Nagell JR; Donaldson ES; Higgins RV
    Gynecol Oncol; 1989 Jul; 34(1):98-100. PubMed ID: 2544491
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Recurrent gestational trophoblastic disease following in-vitro fertilization.
    Tanos V; Meirow D; Reubinoff BE; Anteby SO
    Hum Reprod; 1994 Nov; 9(11):2010-3. PubMed ID: 7532652
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Persistent gestational trophoblastic disease: results of MEA (methotrexate, etoposide and dactinomycin) as first-line chemotherapy in high risk disease and EA (etoposide and dactinomycin) as second-line therapy for low risk disease.
    Dobson LS; Lorigan PC; Coleman RE; Hancock BW
    Br J Cancer; 2000 May; 82(9):1547-52. PubMed ID: 10789722
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Successful resolution of persistent trophoblastic disease after partial mole with the EMA-CO regimen.
    Dgani R; Zalel Y; Biran H; Blickstein I; Caspi B; Weissman A; Shoham Z
    Eur J Obstet Gynecol Reprod Biol; 1994 Mar; 54(1):77-9. PubMed ID: 7519153
    [TBL] [Abstract][Full Text] [Related]  

  • 26. EMACO for treatment of gestational trophoblastic neoplasia: A multinational multicenter study.
    Jareemit N; Therasakvichya S; Freitas F; Paiva G; Ramírez LAC; Berkowitz RS; Horowitz NS; Maestá I; Fülöp V; Braga A; Elias KM
    Gynecol Oncol; 2023 Mar; 170():114-122. PubMed ID: 36682089
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Placental site trophoblastic tumor: an overview.
    Bonazzi C; Urso M; Dell'Anna T; Sacco S; Buda A; Cantú MG
    J Reprod Med; 2004 Aug; 49(8):585-8. PubMed ID: 15457847
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The management of high-risk gestational trophoblastic tumours (GTT).
    Newlands ES; Bower M; Holden L; Short D; Brock C; Rustin GJ; Begent RH; Bagshawe KD
    Int J Gynaecol Obstet; 1998 Apr; 60 Suppl 1():S65-70. PubMed ID: 9833617
    [TBL] [Abstract][Full Text] [Related]  

  • 29. EMA/CO regimen in high-risk gestational trophoblastic tumor (GTT).
    Bolis G; Bonazzi C; Landoni F; Mangili G; Vergadoro F; Zanaboni F; Mangioni C
    Gynecol Oncol; 1988 Nov; 31(3):439-44. PubMed ID: 2846414
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Management of high-risk gestational trophoblastic disease.
    Surwit EA
    J Reprod Med; 1987 Sep; 32(9):657-62. PubMed ID: 2822919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A prospective randomized comparison of methotrexate, dactinomycin, and chlorambucil versus methotrexate, dactinomycin, cyclophosphamide, doxorubicin, melphalan, hydroxyurea, and vincristine in "poor prognosis" metastatic gestational trophoblastic disease: a Gynecologic Oncology Group study.
    Curry SL; Blessing JA; DiSaia PJ; Soper JT; Twiggs LB
    Obstet Gynecol; 1989 Mar; 73(3 Pt 1):357-62. PubMed ID: 2536911
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Results with the EMA/CO (etoposide, methotrexate, actinomycin D, cyclophosphamide, vincristine) regimen in high risk gestational trophoblastic tumours, 1979 to 1989.
    Newlands ES; Bagshawe KD; Begent RH; Rustin GJ; Holden L
    Br J Obstet Gynaecol; 1991 Jun; 98(6):550-7. PubMed ID: 1651757
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Chemotherapy for trophoblastic disease: current standards.
    Kendall A; Gillmore R; Newlands E
    Curr Opin Obstet Gynecol; 2002 Feb; 14(1):33-8. PubMed ID: 11801874
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Central nervous system involvement in gestational trophoblastic neoplasia.
    Altintaş A; Vardar MA
    Eur J Gynaecol Oncol; 2001; 22(2):154-6. PubMed ID: 11446484
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Management of high-risk gestational trophoblastic disease.
    Lurain JR
    J Reprod Med; 1998 Jan; 43(1):44-52. PubMed ID: 9475149
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [EMA/CO regimen for chemotherapy 24 patients with ultra high-risk gestational trophoblastic neoplasia].
    Shen T; Chen LL; Qin JL; Wang XY; Cheng XD; Xie X; Lyu WG
    Zhonghua Fu Chan Ke Za Zhi; 2018 Jun; 53(6):371-376. PubMed ID: 29961278
    [No Abstract]   [Full Text] [Related]  

  • 37. [Methotrexate in gynecologic oncology].
    Isonishi S; Terashima Y
    Gan To Kagaku Ryoho; 1996 Dec; 23(14):1896-900. PubMed ID: 8978793
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Chemotherapy-resistant gestational trophoblastic neoplasia treated successfully with cisplatin, etoposide, and bleomycin.
    Willemse PH; Aalders JG; Bouma J; Sleijfer DT
    Obstet Gynecol; 1988 Mar; 71(3 Pt 2):438-40. PubMed ID: 2450325
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Conservative Chemotherapy in Gestational Trophoblastic Disease: Experience With Etoposide, Methotrexate, and Dactinomycin Chemotherapy.
    Byun SW; Park TC; Bae SN
    Int J Gynecol Cancer; 2016 May; 26(4):790-5. PubMed ID: 27057813
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Clinical characteristics of gestational trophoblastic disease at a single institute.
    Alici S; Eralp Y; Saip P; Argon A; Basaran M; Topuz E; Aydiner A
    Tohoku J Exp Med; 2002 Jun; 197(2):95-100. PubMed ID: 12233789
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.